Genitourinary Cancers Symposium (ASCO GU)

Petros Grivas, MD, PhD, discusses key baseline characteristics from the real-world PATRIOT II study of first-line avelumab maintenance therapy in metastatic urothelial cancer. 

Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.

The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.

The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.

First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

The PARP inhibitor rucaparib improved median radiographic progression-free survival by 4.8 months compared with physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer.

The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.

Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.

Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.

Transurethral resection of bladder tumor followed by gemcitabine, cisplatin, and nivolumab led to stringent clinical complete responses in patients with muscle-invasive bladder cancer.

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

Boris A. Hadaschik, MD, discusses a post-hoc analysis of subsequent therapies received by patients with prostate cancer treated with apalutamide during the phase 3 SPARTAN trial.

Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Treatment with darolutamide decreased the likelihood of developing metastatic disease or discontinuing treatment because of adverse effects vs treatment with apalutamide or enzalutamide in patients with non-metastatic castration-resistant prostate cancer.

The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

At a nearly 3-year median follow-up, health-related quality-of-life scores were improved or maintained over time among patients with advanced renal cell carcinoma who received with nivolumab plus cabozantinib compared with those who received sunitinib.

The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.